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Abstract
Background  and  objectives:  The  aim  of  our  study  is  to  compare  the  effects  of  sugammadex
and neostigmine,  used  for  neuromuscular  blockage  antagonism,  on  postoperative  nausea  and
vomiting (PONV).
Methods:  Our  study  was  completed  with  98  ASA  I-II  risk  patients  undergoing  endotracheal  intu-
bation under  general  anesthesia.  At  the  end  of  the  surgery  patients  were  randomly  divided  into
two groups  given  2  mg  kg−1 sugammadex  (Group  S)  or  50  g  kg−1 neostigmine  plus  0.2  mg  kg−1
atropine  (Group  N).  Monitoring  and  recording  times  were  set  as  1  hour  postoperative  and  from
1--6, 6--12,  and  12--24  hours.  The  anti-emetic  amounts  administered  were  recorded.
Results: In  the  ﬁrst  hour  postoperative  13  patients  in  Group  N  (27%)  and  4  in  Group  S  (8%)
were observed  to  have  nausea  and/or  vomiting  and  the  difference  was  statistically  signiﬁcant
(p =  0.0016).  During  the  24  hours  of  monitoring  there  was  no  signiﬁcant  difference  in  the  inci-
dence and  severity  of  PONV  (p  >  0.05),  however  the  number  of  patients  given  ondansetron  for
PONV treatment  in  Group  N  was  statistically  signiﬁcantly  higher  than  the  number  in  Group  S
(16 in  Group  N,  6  in  Group  S,  p  <  0.011).
Conclusions:  At  the  end  of  our  study  comparing  neostigmine  with  sugammadex  for  neuromus-
cular blockage  antagonism,  we  found  use  of  sugammadex  had  lower  incidence  of  PONV  in  the
postoperative  1st  hour  and  less  anti-emetic  use  in  24  hours  of  monitoring.
© 2016  Sociedade  Brasileira  de  Anestesiologia.  Published  by  Elsevier  Editora  Ltda.  All  rights
reserved.Please  cite  this  article  in  press  as:  Yag˘an  Ö,  et  al.  Comparison  of  the  effects  of  sugammadex  and  neostigmine  on
postoperative  nausea  and  vomiting.  Rev  Bras  Anestesiol.  2016.  http://dx.doi.org/10.1016/j.bjane.2015.08.003
 This study was carried out at Ordu University Education and Training Hospital.
∗ Corresponding author.
E-mail: ozguryagan@hotmail.com (Ö. Yag˘an).
http://dx.doi.org/10.1016/j.bjane.2015.08.003
0104-0014/© 2016 Sociedade Brasileira de Anestesiologia. Published by Elsevier Editora Ltda. All rights reserved.
ARTICLE IN PRESS+ModelBJANE-706; No. of Pages 6
2  Ö.  Yag˘an  et  al.
PALAVRAS-CHAVE
Sugammadex;
Neostigmina;
Pós-operatório;
Náusea;
Vômito
Comparac¸ão  dos  efeitos  de  sugamadex  e  neostigmina  em  náusea  e  vômito  no
pós-operatório
Resumo
Justiﬁcativa  e  objetivos:  O  objetivo  de  nosso  estudo  foi  comparar  os  efeitos  de  sugamadex  e
neostigmina,  usados  para  o  antagonismo  do  bloqueio  neuromuscular  em  náusea  e  vômito  no
pós-operatório  (NVPO).
Métodos:  O  estudo  foi  concluído  com  98  pacientes  de  risco  ASA  I-II,  submetidos  à  intubac¸ão
traqueal  sob  anestesia  geral.  Ao  ﬁnal  da  cirurgia,  os  pacientes  foram  aleatoriamente  divididos
em dois  grupos  que  receberam  2  mg  kg−1 de  sugamadex  (Grupo  A)  ou  50  g  kg−1 de  neostigmina
mais 0,2  mg  kg−1 de  atropina  (Grupo  N).  Os  tempos  de  monitorac¸ão  e  registro  foram  deﬁnidos
como 1  hora  de  pós-operatório  e  de  1-6,  6-12  e  12-24  horas.  As  quantidades  administradas  de
antieméticos  foram  registradas.
Resultados:  Na  primeira  hora  de  pós-operatório,  13  pacientes  do  Grupo  N  (27%)  e  4  do  Grupo
S (8%)  apresentaram  náusea  e/ou  vômito  e  a  diferenc¸a  foi  estatisticamente  signiﬁcativa
(p =  0,0016).  Não  houve  diferenc¸a  signiﬁcativa  na  incidência  e  gravidade  de  NVPO  (p  >  0,05)
durante  as  24  horas  de  monitorac¸ão,  porém  o  número  de  pacientes  que  recebeu  ondansetron
para o  tratamento  de  NVPO  no  Grupo  N  foi  estatística  e  signiﬁcativamente  maior  que  o  número
de pacientes  no  Grupo  S  (16  e  6,  respectivamente,  p  <  0,011).
Conclusões:  Ao  ﬁnal  do  estudo  quando  comparamos  neostigmina  com  sugamadex  para  o  antag-
onismo do  bloqueio  neuromuscular  descobrimos  que  sugamadex  apresentou  menor  incidência
de NVPO  na  primeira  hora  de  pós-operatório  e  consumo  menor  de  antiemético  em  24  horas  de
monitorac¸ão.
© 2016  Sociedade  Brasileira  de  Anestesiologia.  Publicado  por  Elsevier  Editora  Ltda.  Todos  os
direitos reservados.
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introduction
ostoperative  nausea  and  vomiting  (PONV)  has  been  one
f  the  most  important  problems  of  anesthesia  through  the
ears.  Kapur1 described  PONV  as  the  ‘‘Big  Little  Problem’’
n  1991.  While  Watcha2 touched  on  Kapur’s  deﬁnition,  he
ummarized  his  own  views  of  PONV  as  the  ‘‘Big  Big  Prob-
em’’.  PONV  is  one  of  most  common  complications  after
eneral  anesthesia  that  may  cause  increased  morbidity  and
rolonged  hospital  stay.3 Duration  of  anesthesia,  type  of
urgery,  postoperative  analgesia  with  opioids,  as  well  as
atient  related  factors  such  as  age,  gender,  smoking  habits
nd  previous  history  of  PONV  and  of  motion  sickness  are
nown  as  risk  factors  for  developing  PONV.3--5
Neuromuscular  blocker  medications  are  a  necessary  part
f  general  anesthesia.  Additionally  at  the  end  of  the  surgical
rocedure  the  majority  of  times  the  residual  neuromuscu-
ar  block  is  reversed  with  acetyl  choline  esterase  inhibitors.6
holinesterase  inhibitors  have  been  implicated  in  the  devel-
pment  of  PONV  as  a  result  of  their  potent  muscarinic
ffects  upon  the  gastrointestinal  tract  and  the  vomiting
enter  in  the  brain.7 Neostigmine,  used  at  the  end  of
urgery  for  residual  neuromuscular  block,  is  associated  with
ncreased  the  risk  of  PONV,  especially  when  used  in  large
oses  (>2.5  mg).7 Some  previous  studies  have  recommended
voiding  the  use  of  acetyl  choline  esterase  inhibitors  toPlease  cite  this  article  in  press  as:  Yag˘an  Ö,  et  al.  Compar
postoperative  nausea  and  vomiting.  Rev  Bras  Anestesiol.  2016.
educe  postoperative  vomiting.8
Sugammadex  is  a    cyclodextrin  agent  that  selectively
inds  steroidal  neuromuscular  blockers  such  as  rocuronium.
y  making  complexes  with  rocuronium  in  circulation  and  at
e
s
U
seuromuscular  junction,  it  enables  the  excretion  of  the  drug
n  the  urine  without  metabolization.9 Sugammadex  gives
ise  to  safe  and  rapid  reversal  of  neuromuscular  blockade
nduced  by  rocuronium.10,11 Sugammadex  is  known  as  a  safe
rug  without  any  known  serious  side  effects.  The  common
ide  effects  of  sugammadex  are  minimal  cough,  oral  dis-
omfort,  hypersensitivity,  temporary  QT  prolongation  and
emporary  (<30  min)  activated  partial  thromboplastin  time
rolongation.12 The  studies  on  the  effects  of  sugammadex
n  PONV  are  very  limited.13
The  hypothesis  of  our  study  is  that  use  of  sugammadex  to
ntagonize  the  effects  of  neuromuscular  blocker  agents  will
educe  postoperative  nausea  and  vomiting  when  compared
ith  neostigmine.  With  the  aim  of  testing  this  hypothesis
e  aimed  to  compare  the  effects  of  2  mg  kg−1 sugammadex
nd  50  g  kg−1 neostigmine  on  the  incidence  of  PONV.  We
eﬁned  the  major  outcome  as  presence  of  PONV  at  the
ostoperative  one  hour  period  and  number  of  patients  who
ere  needed  ondansetron  for  symptomatic  treatment  during
4  hours  postoperative  period.
ethod
his  single-blind  prospective  randomized  controlled  study
as  conducted  at  ninety-six  ASA  I  and  II  patients,  aged
n  between  18  and  65  years,  scheduled  to  have  gen-ison  of  the  effects  of  sugammadex  and  neostigmine  on
 http://dx.doi.org/10.1016/j.bjane.2015.08.003
ral  anesthesia  with  endotracheal  intubation  for  elective
urgery.  The  study  was  approved  by  Ethics  Committee  of
niversity  School  of  Medicine  (2014/515)  and  Clinical  Trials
tudy  report  (NCT)  and  conducted  in  accordance  with  the
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Sugammadex  and  neostigmine  on  postoperative  nausea  and  
Declaration  of  Helsinki.  Written  informed  consent  was
obtained  from  all  patients  participating  in  the  study.
Exclusion  criteria  were  including  neurosurgery,  laparo-
scopic,  oncologic,  gynecologic,  breast,  strabismus  and  mid
ear  surgery,  history  of  drug  and  alcohol  abuse,  body
mass  index  (BMI)  >  30  kg  m−2,  use  of  analgesics,  sedative  or
antiemetic  drugs  within  24  hours  before  surgery,  psychiatric
and  neurological  disorders,  allergy  or  contraindication  of
study  drugs.  Additionally  patients  with  more  than  two  hours
surgery  time  were  also  excluded.
No  preanaesthetic  medication  was  administered.  In  the
operating  room,  patients  were  monitored  with  ECG,  non-
invasive  arterial  pressure,  peripheral  O2 saturation  (SpO2)
and  end-tidal  CO2 levels  (Mindray,  BeneView  T8,  Shenzhen,
PR  China).  An  intravenous  line  of  10  mL  kg−1 ringers  lac-
tate  solution  was  infused  via  20G  venous  cannula  through
the  dorsum  of  the  non  dominant  hand.  Using  a  computer
generated  sequence  of  numbers  and  a  sealed  envelope
technique,  patients  were  randomly  divided  into  2  groups:
patients  who  received  neostigmine/atropine  combination
(Group  N,  n  =  50)  or  sugammadex  (Group  S,  n  =  50)  for  rever-
sal  of  neuromuscular  blockade.  Neuromuscular  monitoring
was  carried  out  using  TOF  Watch  SX® (Organon  Ltd.,  Dublin,
Ireland)  acceleromyography,  with  skin  electrodes  located  at
the  ulnar  nerve  trace  for  contractions  of  adductor  pollicis
muscle.
Before  the  operations  to  assess  the  PONV  risks
of  patients,  the  simpliﬁed  Apfel  scoring  system  was
used:  (gender:  male:0,  female:1)  +  (history  of  PONV  or
motion  sickness:  no:0,  yes:1)  +  (smoking  status:  no:0,
yes:1)  +  (anticipated  use  of  postoperative  opioids:  no:0,
yes:1).14 Patients  with  a  score  of  two  were  given  4  mg  iv
dexamethasone  (Deksamet  8  mg/2  mL,  Osel I˙lac¸,  Beykoz,
Istanbul)  before  induction,  while  patients  with  a  score  of
3  and  above  were  additionally  given  4  mg  iv  ondansetron
(Ondaren  4  mg/2  mL,  Vem I˙lac¸,  Mecidiyeköy, I˙stanbul)  at  the
end  of  surgery.15
General  anesthesia  was  induced  by  iv  1  g  kg−1 fentanyl
and  2.5  mg  kg−1 propofol.  With  the  loss  of  consciousness
(loss  of  eyelash  reﬂex),  iv  0.6  mg  kg−1 rocuronium  was
applied.  Orotracheal  intubation  was  performed  when  no
response  was  yielded  with  Train  of  Four  (TOF)  stimulation
of  TOF-Guard.  After  intubation  the  patient  was  mechani-
cally  ventilated  in  the  controlled  mode  where  the  end-tidal
CO2 pressure  was  kept  between  35  and  40  mmHg.  Anes-
thesia  was  maintained  with  2%  sevoﬂurane  in  50%  O2/air
mixture  and  0.2--0.7  g  kg−1 min−1 iv  remifentanil  infu-
sion.  Additional  iv  bolus  of  0.1--0.2  mg  kg−1 rocuronium  was
administered  during  surgical  procedure  provided  that  TOF
ratio  to  be  10%  or  lower.  No  neuromuscular  blocker  agent
was  used  if  the  remaining  time  to  the  end  of  surgery
was  less  than  30  minutes.  At  the  end  of  the  surgery,  anes-
thetic  drug  administration  was  ceased  and  the  patient  was
manually  ventilated  with  100%  oxygen.  According  to  the
randomization  schedule,  antagonization  of  neuromuscular
blockade  was  provided  with  intravenous  administration  of
0.05  mg  kg−1 neostigmine  and  0.02  mg  kg−1 atropine  for  the
patients  in  Group  N  and  2  mg  kg−1 sugammadex  for  thePlease  cite  this  article  in  press  as:  Yag˘an  Ö,  et  al.  Compar
postoperative  nausea  and  vomiting.  Rev  Bras  Anestesiol.  2016.
patients  in  Group  S  when  reappearance  of  the  second  twitch
(T2)  on  the  TOF.  The  patients  were  extubated  after  aspi-
ration  of  oropharyngeal  secretions  with  the  90%  recovery
of  TOF  value.  Additional  iv  administration  of  0.025  mg  kg−1
K
t
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iting  3
eostigmine  and  0.01  mg  kg−1 atropine  in  Group  N  and
 mg  kg−1 sugammadex  in  Group  S  was  planned  in  case  of
eed  (should  the  TOF  value  stay  under  90%  after  5  minutes).
In  all  patients  iv  1  gr  paracetamol  (Parol  10  mg  mL−1,
tabay,  Kadıköy, I˙stanbul)  infusion  was  administered  for
ostoperative  analgesia  at  end  of  the  surgery  and  every  8
ours  in  ﬁrst  postoperative  day.  Pain  was  assessed  using  a
isual  analog  scale  (VAS)  from  1  to  10.  Intravenous  50  mg
exketoprofen  (Arveles  50  mg/2  mL,  Ufsa I˙lac¸,  Topkapı,
stanbul)  was  given  on  when  VAS  score  >4.  Administration
f  iv  1  mg  kg−1 tramadol  (Contramal  50  mg  mL−1,  A˙I,  Sarıyer,
stanbul)  for  postoperative  analgesia  were  planned  as  rescue
gents.
The  patients  were  monitored  and  assessed  for  24  hours;
ourly  for  the  ﬁrst  6  hours,  every  2  hours  in  the  6--12  hours
nterval  and,  subsequently,  every  4  hours.  They  were  asked
peciﬁcally  about  pain,  nausea,  vomiting  and  other  side
ffect.  In  all  patients,  nausea  and  vomiting  were  assessed
y  the  same  researcher  (NT)  using  a  four  point  verbal
escriptive  scale  as  described  in  previous  studies:  0 =  not
auseated,  1  =  nauseated,  not  vomiting,  2  =  nauseated,  one
o  two  episodes  of  vomiting,  3  =  nauseated,  more  than  two
pisodes  of  vomiting  during  the  observation  period).16
In  the  presence  of  continuing  nausea  (>5  min)  or  active
omiting,  iv  4  mg  ondansetron  was  administered,  if  not  given
s  prophylactic.  If  ondansetron  was  previously  administered
he  medication  was  not  given  again  within  6  hours  but  meto-
lopramide  0.2  mg  kg−1 was  given  instead.
Patient  characteristics,  type  of  surgery,  amount  of  opi-
id  consumption  and  duration  of  anesthesia  were  recorded.
omplications  after  the  surgery  such  as  headache,  cough,
espiratory  depression,  hypertension,  bradycardia,  sore
hroat,  gastrointestinal  system  complaints  were  also  noted.
R  below  50  pulse  min−1 was  considered  as  bradycardia  and
anaged  with  0.5  mg  iv  atropine.  MAP  above  125  mmHg
as  considered  as  hypertension  and  managed  with  0.1  mg
v  nitroglycerin.
ower  analysis
n  a  previous  study,16 the  incidence  of  PONV  was  reported
s  30%  with  the  same  neostigmine  dose  as  our  study  while  it
as  11%  with  placebo.  According  to  an  evaluation  based  on
 this  study,  44  patients  in  each  group  would  be  required  in
rder  to  detect  20%  change  with  80%  power  and  5%  signiﬁ-
ance  (˛  =  0.05,  ˇ  =  0.80)  in  two  way  signiﬁcant  interactions
Minitab  13.1  Inc.,  State  College,  PA,  USA).  We  planned  to
nclude  100  patients  in  this  study  to  allow  for  dropouts.
tatistical  analysis
ata  obtained  in  the  study  were  analyzed  with  SPSS
6.0  (IBM  SPSS  Statistics,  Chicago,  IL,  USA).  Descriptive
tatistics  were  stated  as  mean  ±  standard  deviation  for
ontinuous  variables  and  as  number  and  percentage  for
ominal  variables.  Distribution  analysis  was  made  with  theison  of  the  effects  of  sugammadex  and  neostigmine  on
 http://dx.doi.org/10.1016/j.bjane.2015.08.003
olmogorov--Smirnov  test.  Age,  BMI,  remifentanil  consump-
ion,  surgery  time  were  evaluated  with  student  t  test.  The
hi-square  or  the  Fisher  exact  test  was  used  for  categori-
al  data  such  as  gender,  ASA  physical  status,  rate  of  PONV,
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Table  1  Patients  and  clinical  characteristics.
Group  N
n =  48
Group  S
n =  50
p
Age  (yr)  40.8  ±  11.2  40.3  ±  13.3  NS
Weight (kg) 73  ±  9.2 71  ±  10.5 NS
BMI  (kg  m−2) 23.9  ±  3.5 22.8  ±  3.6 NS
Gender  (F/M)  18/30  16/34  NS
ASA I/II  37/11  36/14  NS
Apfel score
0/1/2/3  (n)
14/20/14/0  16/19/15/0  NS
Surgery  time
(min)
49.9  ±  22.3  54.7  ±  22.0  NS
Remifentanil
consumption
(g)
624  ±  196  681  ±  186  NS
NS, not signiﬁcant; BMI, Body mass index; F/M, female/male;
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Table  2  Incidence  and  severity  of  PONV  and  antiemetic
and analgesic  treatment  in  groups.
Group  N
n =  48
Group  S
n =  50
p
PONV  at  PACU 0.016
No 35  (73%) 46  (92%)
Yes  13  (27%)  4  (8%)
PONV  at  PACU NS
0 35  (73%)  46  (92%)
1 9  (19%)  3  (6%)
2 3  (6%)  1  (2%)
3 1  (2%)  0
1--6  hours NS
0 43  (90%)  48  (96%)
1 4  (8%)  2  (4%)
2 1  (2%)  0
6--12  hours NS
0 45  (94%)  50  (100%)
1 3  (6%)  0
2 0  0
Antiemetic
treatment  (n)
(Ondansetron)
16  (33%)  6  (12%)  0.011
Analgesic
treatment  (n)
(Dexketoprofen)
14  (30%)  17  (34%)  NS
Analgesic
treatment  (n)
(Tramadol)
3  (6%)  4  (8%)  NS
Data are presented as frequencies. PONV, Postoperative nausea
and vomiting; PACU, Postanesthetic care unit. PONV was  evalu-
ated as follows: 0 = not nauseated, 1 = nauseated, not vomiting,
2 = nauseated, one to two episodes of vomiting, 3 = nauseated,
more than two episodes of vomiting.
Table  3  Postoperative  side  effects.
Group  N
n =  48
Group  S
n =  50
p
Headache  4  (8%)  2  (4%)  NS
Hypertension  2  (4%)  3  (6%)  NS
Bradycardia  2  (4%)  0  NS
Coughing  2  (4%)  0  NS
Shivering  0  1  (2%)  NS
Sore throat 1  (2%) 0  NS
n
n
ﬁ
t
o
oASA, American Society of Anesthesiologist.
Data are presented as mean ± SD or frequencies.
ide  effects.  A  value  of  p  <  0.05  was  accepted  as  statistically
igniﬁcant.
esults
he  study  included  two  groups  with  50  patients  in  each
roup.  Two  patients  in  Group  N  were  excluded  from  the  study
s  their  surgeries  lasted  more  than  2  hours.  The  demographic
ata  in  both  groups  were  similar  (Table  1).  There  was  no  sig-
iﬁcant  difference  between  the  patients  in  terms  of  PONV
isk  scores,  surgical  durations  and  consumed  remifentanil
mounts  (Table  1).  In  Group  N,  24  patients  (50%)  underwent
ead  and  neck  surgery,  13  (27%)  had  urology,  4  (8%)  had
rthopedic  and  7  patients  (15%)  had  general  surgery  pro-
edures.  In  Group  S,  29  patients  (58%)  had  head  and  neck
urgery,  11  (22%)  had  urology,  5  (10%)  had  orthopedic  and
 patients  (10%)  had  general  surgery  procedures.  There  was
o  statistically  signiﬁcant  difference  between  the  groups  in
erms  of  type  of  surgery  undergone  (p  >  0.05).
In  the  post  anesthesia  care  unit  (PACU)  during  1  hour  post-
perative  monitoring,  13  patients  in  Group  N  (27%)  and  4
atients  in  Group  S  (8%)  had  nausea  and/or  vomiting.  The
ate  was  higher  by  a  statistically  signiﬁcant  degree  in  Group
 (p  =  0.016).  In  the  later  24  hour  monitoring,  there  was
o  statistically  signiﬁcant  difference  observed  in  the  inci-
ence  and  severity  of  PONV  between  the  groups  (p  >  0.05,
able  2).  However  the  number  of  patients  given  ondansetron
n  Group  N  was  signiﬁcantly  high  (16  patients  in  Group  N,  6  in
roup  S,  p  =  0.011).  The  postoperative  analgesic  treatments
n  both  groups  were  similar  (Table  2).  There  was  no  signiﬁ-
ant  difference  between  the  groups  in  terms  of  side  effects
Table  3).
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eostigmine,  used  to  antagonize  the  effects  of  neuromus-
ular  blocker  agents,  on  incidence  of  postoperative  nausea
nd  vomiting,  less  PONV  was  observed  in  the  ﬁrst  hour
ostoperative  with  the  use  of  sugammadex  compared  to
n
a
n
tRespiratory  depression  2  (4%)  0  NS
Data are presented as frequencies.
eostigmine.  Our  cases  administered  sugammadex  had  a  sig-
iﬁcant  reduction  in  the  amount  of  anti-emetics  used  in  the
rst  24  hours  postoperative  compared  with  cases  adminis-
ered  neostigmine.
Many  studies  have  reported  the  emetic  effect  of  the  use
f  high-dose  neostigmine  for  neuromuscular  blockage  antag-
nism.  King  et  al.17 in  a  study  researching  the  effects  of
eostigmine  on  PONV,  administered  one  group  neostigmine-ison  of  the  effects  of  sugammadex  and  neostigmine  on
 http://dx.doi.org/10.1016/j.bjane.2015.08.003
tropine  for  neuromuscular  blockage  antagonism  and  used
o  medication  for  the  other  group.  In  conclusion  they  iden-
iﬁed  a  signiﬁcant  difference  with  higher  nausea  by  68%  to
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Sugammadex  and  neostigmine  on  postoperative  nausea  and  
32%  and  vomiting  by  47%  to  11%  in  the  neostigmine-atropine
group.  Ding  et  al.18 studied  laparoscopic  tubal  ligation  and
found  signiﬁcantly  more  PONV  in  the  PACU  when  neostigmine
was  compared  with  placebo  after  mivacurium,  65%  versus
25%  respectively.  Meta-analyses  demonstrate  that  high-dose
neostigmine  (>2.5  mg)  is  associated  with  increased  PONV  and
that  reducing  the  dose  can  decrease  PONV  risk.7,19
However,  the  clinical  importance  of  neostigmine’s  effects
on  PONV  has  been  questioned.  The  results  of  a  meta-analysis
study  including  15  studies,  found  the  evidence  that  neostig-
mine  increased  the  risk  of  PONV  to  be  insufﬁcient.20 A
study  researching  the  effects  of  neostigmine  on  PONV  after
abdominal  hysterectomy  operations  left  one  group  to  spon-
taneously  recover  from  neuromuscular  blockage  induced  by
mivacurium  while  the  other  group  was  antagonized  with
2  mg  neostigmine.  They  did  not  ﬁnd  a  signiﬁcant  difference
between  the  groups  in  terms  of  both  nausea  and  vomiting.  In
conclusion  they  stated  that  the  use  of  neostigmine  for  neu-
romuscular  block  antagonism  did  not  increase  the  incidence
or  severity  of  PONV.21 It  has  been  reported  that  neuromuscu-
lar  block  antagonism  with  2  mg  neostigmine  in  laparoscopic
gynecological  operations  did  not  cause  an  increase  in  the
incidence  of  PONV.22 The  noticeable  point  in  these  two
studies  is  the  amount  of  neostigmine  used.  It  has  been
determined  that  use  of  neostigmine  in  doses  above  2.5  mg
increases  the  risk  of  PONV.7,15-17
A  study  by  Lovstad  et  al.16 compared  the  effect  of
50  g  kg−1 dose  of  neostigmine  with  a  placebo  group  on
PONV  in  women  after  laparoscopic  gynecology  operations.
At  the  end  of  surgery  all  patients  were  given  iv  0.05  mg  kg−1
ondansetron.  In  the  ﬁrst  6  hours  they  found  the  nau-
sea  rate  in  the  neostigmine  group  was  30%,  while  in  the
placebo  group  this  rate  was  11%.  The  necessity  for  rescue
anti-emetic  medication  (metoclopramide  0.2  mg  kg−1 and
droperidol  0.025  mg  kg−1)  was  28%  in  the  neostigmine  group
and  7%  in  the  placebo  group.  They  reported  that  both  these
differences  were  statistically  signiﬁcant.  The  researchers
did  not  ﬁnd  a  signiﬁcant  difference  in  vomiting  rates  in  the
ﬁrst  6  hours.  Monitoring  from  6  to  24  hours,  the  so-called  late
period,  observed  no  signiﬁcant  difference  in  either  nausea
or  vomiting.  In  conclusion  this  study  reported  that  high  dose
neostigmine  for  neuromuscular  blockage  antagonism  caused
an  increase  in  the  risk  of  nausea  in  the  ﬁrst  6  hours  after
surgery  for  women  undergoing  laparoscopic  surgery,  even
with  ondansetron  prophylaxis.  The  dose  of  neostigmine  used
in  this  study,  when  the  weight  of  the  patients  in  the  study  is
taken  into  account,  is  above  the  2.5  mg  dose  stated  to  cause
an  increased  risk  of  PONV.
The  studies  assessing  the  effect  on  postoperative  nausea
and  vomiting  when  sugammadex  and  neostigmine  are  used
to  reverse  the  effect  of  neuromuscular  blocker  agents  are
very  limited.  According  to  the  results  of  a  study  assessing
postoperative  results  of  neuromuscular  blockage  antago-
nism  and  including  1440  patients  (772  sugammadex,  212
neostigmine,  510  no  reversal),  the  incidence  of  PONV  in  the
PACU  was  found  to  be  signiﬁcantly  high  in  the  neostigmine
group  compared  to  the  sugammadex  group  (21.5%  vs.  13.6%,
p  <  0.05).  The  researchers  did  not  determine  any  signiﬁ-Please  cite  this  article  in  press  as:  Yag˘an  Ö,  et  al.  Compar
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cant  difference  between  the  sugammadex  and  no-reversal
groups.  In  a  study  which  reported  the  use  of  intraoperative
anti-emetics  was  more  frequent  in  the  neostigmine  group,
they  emphasized  that  the  cause  of  increased  risk  of  PONV
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n  the  sugammadex  group  was  urgent  surgery  and  abdomi-
al  surgical  procedures.  When  the  researchers  assessed  the
esults  of  the  study  they  stated  that  the  cost  increase  caused
y  use  of  sugammadex  was  off-set  by  the  reduction  in  inci-
ence  of  PONV.23
A  study  by  Koyuncu  et  al.13 compared  the  effects  of
0  g  kg−1 neostigmine  and  2  mg  kg−1 sugammadex  on  PONV
hen  used  for  neuromuscular  blockage  antagonism  in  100
atients  undergoing  extremity  surgery.  In  the  study  with
nduction  of  anesthesia  using  propofol,  fentanyl  and  rocuro-
ium  while  maintenance  used  desﬂurane  and  nitrous  oxide
ith  oxygen,  0.5  mg  kg−1 iv  meperidine  was  administered
t  the  end  of  surgery  for  postoperative  analgesia.  They  did
ot  administer  intraoperative  anti-emetic  medication.  PONV
as  treated  with  4  mg  ondansetron  iv  and  if  it  continued
0  mg  metoclopramide  iv.  When  the  ﬁndings  of  the  study
re  evaluated,  though  there  was  no  difference  in  anesthesia
urations  and  Apfel  scores  of  patients,  they  stated  that  the
ausea  and  vomiting  scores  in  the  PACU  were  statistically  sig-
iﬁcantly  lower  in  the  sugammadex  group.  However  during
4  hours  postoperative  nausea  and  vomiting  was  observed  in
0%  of  the  sugammadex  group  and  58%  of  the  neostigmine
roup  and  they  reported  there  was  no  signiﬁcant  difference.
n  conclusion  comparing  sugammadex  with  neostigmine  they
etermined  that  there  was  a  slight  and  temporary  reduc-
ion  in  the  incidence  of  PONV.  They  did  not  ﬁnd  a  positive
ffect  of  the  return  of  gastrointestinal  functions  and  ambu-
ation.  The  researchers  linked  their  high  rates  of  PONV,  when
ompared  to  the  literature,  to  the  use  of  nitrous  oxide  for
nesthesia  maintenance  and  the  use  of  opioids  for  postop-
rative  analgesia.13
The  results  of  our  study  are  similar  to  the  study  by
oyuncu  et  al.13 in  identifying  a  lower  PONV  incidence  in
he  1st  hour  of  monitoring  in  PACU  with  sugammadex.  How-
ver  in  the  24  hour  monitoring  period,  the  study  by  Koyuncu
t  al.  had  different  and  higher  results  than  in  the  litera-
ure  and  our  study.  In  our  study  during  the  postoperative
--6  hours  the  nausea  and  vomiting  incidence  was  10%  in
roup  N  and  4%  in  Group  S,  while  between  6  and  24  hours
t  was  found  to  be  6%  in  Group  N  and  0%  in  Group  S.  We
elieve  the  basic  reason  for  the  differences  from  the  results
f  Koyuncu  et  al.  is  that  in  situations  with  Apfel  score  of  2
nd  above  we  administered  antiemetic  medication.  Another
mportant  reason  may  be  the  amount  of  neostigmine  used.
oyuncu  et  al.  used  70  g  kg−1 in  their  study.  In  our  study
he  dose  of  neostigmine  was  50  g  kg−1,  which  is  similar  to
any  studies  in  the  literature.7,16,20 When  the  mean  weights
re  considered,  the  mean  amount  of  neostigmine  used  per
atient  in  our  study  was  3.65  mg,  while  this  was  5.25  mg  in
he  study  by  Koyuncu  et  al.  Other  possible  reasons  may  be
isted  as  differences  in  anesthetic  method  (we  did  not  use
2O  for  maintenance  or  meperidine  for  postoperative  anal-
esia)  and  our  shorter  duration  of  surgery  (about  30  minutes
horter).  It  has  been  determined  that  the  increase  in  surgical
uration  may  increase  the  incidence  of  PONV  (each  30  min
ncrease  in  duration  increases  PONV  risk  by  60%,  so  that  a
aseline  risk  of  10%  is  increased  by  16%  after  30  min).10
In  our  study  in  the  postoperative  24  hour  monitoringison  of  the  effects  of  sugammadex  and  neostigmine  on
 http://dx.doi.org/10.1016/j.bjane.2015.08.003
eriod,  the  number  of  patients  given  anti-emetic  treatment
ith  ondansetron  was  signiﬁcantly  lower  in  the  sugam-
adex  group  (12%  compared  to  33%).  Ledowski  et  al.23 in
 retrospective  scan  reported  similar  results,  with  lower
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nti-emetic  medication  administration  in  the  PACU  for  the
ugammadex  group.
The  most  important  limitation  of  our  study  is  that  though
e  did  not  include  surgeries  known  to  be  risk  factors  for
ONV,  it  was  not  completed  with  a  single  type  of  surgery.
In  conclusion,  this  study  shows  that  neostigmine  reversal
n  increased  PONV  at  PACU  and  use  of  antiemetic  rescue
edication  during  the  postoperative  24  hours.  In  terms  of
ONV,  the  use  of  sugammadex  for  neuromuscular  blockage
ntagonism  may  be  a  better  choice  for  patients  with  high
isk  or  where  this  situation  is  undesirable.
linical trial registration
CT02286752.
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